OST-122

About Oncostellae

Oncostellae is a Spanish biotechnology startup developing innovative, small-molecule therapeutics for oncology and inflammatory/autoimmune diseases. Its strategy centers on creating novel chemical scaffolds targeting clinically validated pathways, with a lead program, OST-122, demonstrating promising Phase 2a proof-of-concept in ulcerative colitis. The company operates a capital-efficient model, advancing programs to clinical proof-of-concept before out-licensing to pharmaceutical partners for late-stage development and commercialization.

Therapeutic Areas